Cancer Patients Turned to China for Sunvozertinib. Now the Drug Is Available in the US

A US launch changes the choices facing families

AstraZeneca announced on October 22, 2026, that sunvozertinib, a cancer medicine some American families had been obtaining in China, was available in the United States under the brand name Zegfrovy. The launch closes an access gap that persisted for more than 15 months after the Food and Drug Administration granted accelerated approval on July 2, 2025.

For Debbie Doppelt, a 60-year-old New York City jeweler whose lung cancer had spread to her brain, that gap had meant relying on medicine brought from overseas. Her son, Max Doppelt, flew to Shanghai and returned with 26 boxes costing about $10,000. By October 2026, she had taken the drug for roughly 19 months, with her cancer mostly controlled alongside radiation treatments and adjustments to her dose.

AstraZeneca's US availability announcement supersedes earlier expectations that the drug would reach American patients by the end of 2026. Eligible patients can now obtain it through a specialty distribution and pharmacy network, including participating health system pharmacies.

The launch changes the immediate decision for patients who meet the approved conditions. The wider problem remains: Americans with advanced cancer are looking abroad when a treatment is unavailable at home, when a trial excludes them, or when the remaining choices seem poorly suited to their disease.

China's expanding drug industry is creating more of those choices. Families considering them must navigate medical evidence, treatment costs, import rules and arrangements for managing complications, often while facing a rapidly advancing illness.

Why one family looked beyond New York

Debbie Doppelt received her diagnosis in late 2023 after developing a persistent cough. Chemotherapy, immunotherapy and surgery controlled her cancer for months. In December 2024, scans revealed 10 small tumors in her brain.

Her cancer carries an EGFR exon 20 insertion mutation. EGFR is a protein involved in signals that tell cells to grow. An exon 20 insertion is a particular change in the gene's instructions that can keep those signals active. Many older medicines targeting EGFR work poorly against this version.

American treatment options existed, but each presented difficulties for the family. Max worried about the toxicity of amivantamab, and several doctors he consulted questioned how effectively it would reach cancer in the brain. In January 2025, his mother was excluded from a zipalertinib trial at Memorial Sloan Kettering Cancer Center because of slight lung scarring.

Sunvozertinib was being studied in the United States, but the relevant trial could assign participants to chemotherapy alone. Debbie's cancer had already progressed after chemotherapy. China had approved sunvozertinib in August 2023, making a pharmacy purchase there another possibility.

Max Doppelt, a computer engineer who organized his mother's care, described what collecting the medicine meant to him:

Getting on the plane and bringing the medicine home felt like my life's purpose.

Max said he knew of at least 30 Americans who traveled to China for sunvozertinib. That is a personal count rather than a national total. He also helped a woman aged 70 who learned after three months that the medicine was not working, despite having obtained a supply intended to last six months.

How approval and access became separated

Sunvozertinib's journey illustrates three different steps: permission to prescribe a drug, commercial distribution and an individual patient's ability to obtain it. These steps can happen months or years apart.

• August 2023: China's National Medical Products Administration approved sunvozertinib for certain advanced lung cancers after previous treatment.
• January 2025: Debbie Doppelt was excluded from the zipalertinib trial and her family sought sunvozertinib from China.
• July 2, 2025: The FDA granted sunvozertinib accelerated approval for eligible adults whose disease progressed on or after platinum chemotherapy.
• September 1, 2026: AstraZeneca signed a worldwide distribution agreement with Dizal Pharmaceutical.
• October 22, 2026: AstraZeneca announced US availability through its specialty distribution and pharmacy network.

The current US indication covers adults with locally advanced or metastatic non-small cell lung cancer carrying an EGFR exon 20 insertion detected by an FDA approved test. Their disease must have progressed on or after platinum chemotherapy. Metastatic means that cancer has spread beyond its original location.

AstraZeneca also says applications for use as an initial treatment have been submitted in the United States and China, supported by the phase 3 WU-KONG28 trial. Both regulators granted Breakthrough Therapy Designation for that setting, a status intended to speed development and review. The announcement gives no decision date for those applications.

What the clinical evidence says

The FDA approval rests on WU-KONG1B, a multinational phase 2 study. In the group highlighted in AstraZeneca's announcement, 85 patients received 200 milligrams daily. Independent reviewers confirmed tumor responses in 46%, or 39 patients.

Among those 39 responders, the median response duration was 11.1 months, and 72% had responses lasting at least six months. A response means that tumors shrank enough to meet the study's measurement rules. The duration figure describes the patients whose tumors responded.

The broader WU-KONG1B study enrolled 202 patients and examined doses of 200 and 300 milligrams. Response rates in the two randomized dose groups were close, at 45.9% and 47.2%. Severe treatment related adverse events occurred in 40.7% at the lower dose and 58.6% at the higher dose, a difference of 17.9 percentage points. No treatment related deaths were reported.

A published Chinese case report provides a more detailed picture of one patient's course. A man aged 67 with stage IVB lung adenocarcinoma started sunvozertinib at 300 milligrams daily on December 15, 2023, after side effects and difficulty obtaining intravenous access led him to stop earlier treatments.

His measured tumor diameter decreased from 4.4 centimeters to 3.8 centimeters. After 13 months on sunvozertinib, his cancer had not progressed. He experienced mild diarrhea and inflammation around the nails, known as paronychia. His total period without progression reached 34 months across several treatments; the authors attributed that longer course potentially to their combined, sequential benefits.

AstraZeneca says continued US approval may depend on confirmation of clinical benefit in further trials. Accelerated approval allows earlier access using measures such as tumor shrinkage and response duration, with additional research required to verify the benefit.

The medicine still requires close monitoring

AstraZeneca's prescribing information warns that Zegfrovy can cause serious lung inflammation, gastrointestinal problems, severe skin reactions and eye toxicity. In its safety population of 121 patients, diarrhea occurred in 73%, eye toxicity in 13%, and interstitial lung disease or pneumonitis in 1.7%.

Interstitial lung disease and pneumonitis involve damage or inflammation in the lungs. New or worsening breathlessness, cough or fever requires prompt medical assessment. The prescribing information directs clinicians to withhold treatment when this complication is suspected and permanently stop it when confirmed.

The different study populations and doses give doctors several sets of safety figures to consider. Debbie Doppelt's need for dose adjustments, and the higher frequency of severe adverse events at 300 milligrams in WU-KONG1B, show why prescribing requires continued supervision.

The US regimen is 200 milligrams once daily with food. Other medicines can change how the body processes sunvozertinib, and the drug can interfere with some hormonal contraceptives. Patients need a clinician to review their complete medication list and manage any changes.

China's role extends beyond a single drug

China accounted for as much as 46% of new drugs tested worldwide in 2025, according to a Goldman Sachs estimate. Its growth also includes CAR-T therapy, which modifies a patient's immune cells so they can recognize and attack cancer. American and European patients are traveling to China for trials of these treatments.

Taletrectinib provides another example of China's expanding targeted cancer treatments. On December 20, 2024, the NMPA approved it as Dovbleron for certain advanced lung cancers carrying ROS1 alterations after earlier treatment with a ROS1 inhibitor. ROS1 is a different growth signal from EGFR, so molecular testing determines which treatment fits a patient's cancer.

In the TRUST-I study, 66 patients previously treated with crizotinib had a confirmed response rate of 51.5% and disease control rate of 83.3%. Disease control includes both tumor shrinkage and disease that remains stable. Median progression-free survival was 7.6 months, meaning half had experienced progression or died by that point and half had not.

Caicun Zhou, director of oncology at Shanghai East Hospital, said taletrectinib showed activity against brain lesions and disease resistant to crizotinib. The drug received breakthrough therapy designations from both American and Chinese regulators, illustrating how development can involve both systems.

Biotechnology executives also describe a shift in where the earliest trials take place. Steve Potts, chief executive of Breakthru Medicine, said nearly all of about 60 biotech chief executives at a meeting in May 2026 planned phase 1 studies in Australia, Europe or China. Phase 1 is usually the first stage of testing a treatment in people, concentrating on safety and dose.

Speed depends on more than review deadlines

A 2019 HKEX industry overview described biologic medicines as typically taking 10 to 15 years from discovery through clinical testing to market. It outlined extensive clinical data requirements and continued safety monitoring after launch.

The historical comparison listed an initial investigational application period of no more than 60 days in China and 30 days in the United States. It listed standard marketing reviews of 200 to 300 working days in China and 10 months in the United States, while noting that individual approval routes vary.

Those published deadlines cover only parts of development. Financing, hospital preparation, recruitment and communication with regulators also affect when a patient can enter a study. Executives describing faster trial starts in China and Australia are discussing that practical process.

Manufacturing adds another layer. The overview explained that small differences in production can change the safety and effectiveness of monoclonal antibodies, medicines made using living cells. For patients considering biologic or cell treatments abroad, the laboratory and manufacturing arrangements are therefore part of the medical decision.

What changes outside the US system

The FDA said in September 2026 that foreign clinical data must meet the same evidentiary standard regardless of geography. In a statement co-authored by leaders of its drug, biologics, device and oncology centers, the agency described good clinical practice as more than paperwork:

not a bureaucratic formality

Good clinical practice includes rules for informed consent, reliable records and protecting participants. A Chinese trial can have national regulatory authorization and ethics approval, while an American participant receives care under that country's consent, oversight and legal arrangements.

Emily Hilliard, a spokesperson for the Department of Health and Human Services, described the FDA's concern about treatment obtained abroad:

cautions patients about potential safety and quality risks associated with treatments outside our regulatory system

The Centers for Disease Control and Prevention warns that medicines, laboratory services and medical devices abroad may face different oversight. Risks include counterfeit products, contamination, expiration and improper storage. Infection related problems are the most common complications among medical tourists, and legal remedies can be more limited.

Personal importation brings a separate set of rules. Unapproved drugs are generally prohibited, although the FDA may exercise discretion for a serious condition when effective treatment may be unavailable domestically. Its policy generally contemplates no more than a three month supply and information identifying the responsible US physician, or evidence that treatment began abroad. Families should discuss the current status of their medicine with their oncologist before arranging a purchase.

Research policy also involves cells, consent and security

The FDA took a separate action on June 18, 2025, suspending certain new trials that sent Americans' living cells to China and other countries for genetic engineering before reinfusion into patients. The agency cited concerns that participants sometimes lacked knowledge of, or had not consented to, the transport and subsequent infusion.

FDA Commissioner Marty Makary also raised concerns about some receiving companies being partly owned or controlled by the Chinese Communist Party. The action followed a data security rule finalized in December 2024 and effective in April 2025; the FDA said an exemption had allowed clinical trial samples, including DNA, to be sent overseas.

For someone considering cell therapy, those issues translate into concrete consent questions: where the cells travel, who handles them, what genetic work takes place and how the resulting product is tested before treatment.

The Trump administration launched Operation TrialBlazer in June 2026 to accelerate some FDA processes and attract early trials to the United States. Representatives John Moolenaar and Debbie Dingell also co-sponsored legislation requiring Treasury Department clearance for US pharmaceutical deals with Chinese companies.

Peter Kolchinsky, managing partner of RA Capital Management, which has Chinese biotech investments, argued for cooperation in developing cancer medicines:

We may be adversaries in many areas, but we're not competing with them to cure cancer. We are collaborating with them to cure cancer.

What families need before arranging treatment abroad

About 7% of American cancer patients enter clinical treatment trials. Max Doppelt developed a free application using artificial intelligence to match medical records with trial information; about 300 patients had used it. Finding a possible study is an opening step, followed by a medical assessment of eligibility, benefit and risk.

A US oncologist can check whether a newly available medicine or domestic trial fits the patient's mutation and treatment history. ClinicalTrials.gov also lists many international studies. Families considering an overseas trial should request its registration details, ethics approval, study plan and consent form in English.

The overseas team should explain how adverse effects are monitored, how long the patient must remain nearby and who pays for complications. For medicines taken home, families need reliable manufacturing, storage and shipping arrangements, plus complete records documenting every drug and dose.

Insurance coverage deserves attention before departure because many US plans exclude treatment abroad. Patients should arrange who will manage side effects after their return and consider coverage for medical evacuation. Fever, shortness of breath, chest pain, confusion or severe weakness after treatment warrants urgent care, with clinicians told where and how treatment occurred.

Zegfrovy's US launch removes one reason eligible patients had sought this particular drug overseas. For other experimental treatments, the same practical questions remain central: access to the right study, understandable consent, dependable production and care that continues when the patient comes home.

Key Points

• AstraZeneca announced US availability of Zegfrovy on October 22, 2026, more than 15 months after FDA accelerated approval.
• The approved use covers certain EGFR exon 20 insertion lung cancers that progressed on or after platinum chemotherapy.
• In the principal efficacy group, 46% of 85 patients responded; median response duration among responders was 11.1 months.
• The drug requires monitoring for lung inflammation, diarrhea, skin reactions, eye problems and medication interactions.
• China's expanding drug and cell therapy research is attracting patients whose options at home are limited.
• Overseas treatment requires careful planning for consent, costs, import rules, medical records and continuing care.